Skip main navigation
Close Drawer MenuOpen Drawer Menu
Practice Guidelines

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Full Access

Acronyms/Abbreviations

Acronyms/Abbreviations

  • ACT Assertive community treatment

  • AHRQ Agency for Healthcare Research and Quality

  • AIMS Abnormal Involuntary Movement Scale

  • ANC Absolute neutrophil count

  • APA American Psychiatric Association

  • BAP British Association for Psychopharmacology

  • BMI Body mass index

  • BPRS Brief Psychiatric Rating Scale

  • CATIE Clinical Antipsychotic Trials of Intervention Effectiveness

  • CBT Cognitive-behavioral therapy

  • CBTp Cognitive-behavioral therapy for psychosis

  • CDC Centers for Disease Control and Prevention

  • CGI Clinical Global Impression

  • CI Confidence interval

  • CrI Credible interval

  • CSC Coordinated specialty care

  • CSG Canadian Schizophrenia Guidelines

  • CYP Cytochrome P450

  • DISCUS Dyskinesia Identification System: Condensed User Scale

  • DSM Diagnostic and Statistical Manual of Mental Disorders

  • DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition

  • ECG Electrocardiography

  • ECT Electroconvulsive therapy

  • FDA U.S. Food and Drug Administration

  • FGA First-generation antipsychotic

  • GAF Global Assessment of Functioning

  • GRADE Grading of Recommendations Assessment, Development and Evaluation

  • HIPAA Health Insurance Portability and Accountability Act

  • HIV Human immunodeficiency virus

  • HR Hazard ratio

  • ICD International Classification of Diseases

  • IPS Individual placement and support

  • LAI Long-acting injectable

  • MD Mean difference

  • NICE National Institute for Health and Care Excellence

  • NMDA N-methyl-d-aspartate

  • NMS Neuroleptic malignant syndrome

  • NNH Number needed to harm

  • NNT Number needed to treat

  • NQF National Quality Forum

  • OR Odds ratio

  • PANSS-6 Positive and Negative Syndrome Scale, 6-item version

  • PANSS-30 Positive and Negative Syndrome Scale, 30-item version

  • PORT Schizophrenia Patient Outcomes Research Team

  • PROMIS Patient-Reported Outcomes Measurement Information System

  • RAISE Recovery After an Initial Schizophrenia Episode

  • RANZCP Royal Australian and New Zealand College of Psychiatry

  • RCT Randomized controlled trial

  • REMS Risk Evaluation and Mitigation Strategy

  • RR Relative risk

  • SANS Scale for the Assessment of Negative Symptoms

  • SAPS Scale for the Assessment of Positive Symptoms

  • SD Standard deviation

  • SFS Social Functioning Scale

  • SGA Second-generation antipsychotic

  • SIGN Scottish Intercollegiate Guidelines Network

  • SMD Standardized mean difference

  • SOE Strength of evidence

  • SOFAS Social and Occupational Functioning Assessment Scale

  • TdP Torsades de pointes

  • TMS Transcranial magnetic stimulation

  • TRRIP Treatment Response and Resistance in Psychosis

  • UKU Udvalg for Kliniske Undersogelser

  • VMAT2 Vesicular monoamine transporter 2

  • WFSBP World Federation of Societies of Biological Psychiatry

  • WHODAS 2.0 World Health Organization Disability Schedule 2.0

  • WHOQOL-BREF World Health Organization Quality of Life scale

  • WMD Weighted mean difference

  • XR Extended release